IXICO plc - Investor presentation

RNS Number : 2263X
26 August 2020


("IXICO" or the "Company")


Investor presentation

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that a recording of the online Company presentation, delivered by Giulio Cerroni, Chief Executive Officer, and Grant Nash, Chief Finance Officer, on Tuesday 25 August, surrounding the Company's recent trading update, is now available to watch back on the Investor Meet Company platform. The Q&A has also been published following the meeting.

Investors can sign up to Investor Meet Company for free and add to meet IXICO plc via the following link, which will take you to the recording of the presentation and the Q&A:  https://www.investormeetcompany.com/ixico-plc/register-investor

No new price-sensitive information is disclosed as part of the presentation.


For further information please contact:


  IXICO plc

+44 (0)20 3763 7498

  Giulio Cerroni, Chief Executive Officer

  Grant Nash, Chief Financial Officer




  Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0)20 7397 8900

  Giles Balleny / Max Gould (Corporate Finance)


  Michael F Johnson / Russell Kerr (Sales)




  Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected]


  Paul McManus / Lianne Cawthorne /

Mob: 07980 541 893 / 07584 391 303 /

  Alice Woodings

07407 804 654




IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.


IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.


More information is available on www.IXICO.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.

Quick facts: IXICO PLC

Price: 105

Market: AIM
Market Cap: £49.45 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


IXICO revenues' rise for fourth consecutive year, up by 26%

IXICO PLC's (LON:IXI) Giulio Cerroni talks to Proactive London about his artificial intelligence-driven data analytics company. Cerroni explains the latest set of results, which show revenue rose by 26% to £9.5m, up from £7.6m the year before. He also highlights the order book which grew...

6 days, 15 hours ago

3 min read